Insight Molecular Diagnostics Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $4.1M | $1.9M | $1.5M | $958,000 | $2.2M |
| Gross profit | $2.3M | $740,000 | $413,000 | -$18,000 | $1.4M |
| Operating income | -$51.1M | -$61.0M | -$25.1M | -$18.0M | -$53.7M |
| Operating expenses | $53.4M | $61.8M | $25.5M | $18.0M | $55.1M |
| Cost of revenue | $1.8M | $1.1M | $1.0M | $880,000 | $697,000 |
| Cash from operations | -$22.2M | -$20.7M | -$23.3M | -$45.6M | -$35.9M |
| Capital expenditure | $3.2M | $516,000 | $281,000 | $4.3M | $2.2M |
| Free cash flow | -$25.4M | -$21.2M | -$23.6M | -$49.9M | -$38.2M |
| Impairments | $14.6M | $169,000 | $1.3M | $18.7M | — |
| Total assets | $25.8M | $35.1M | $74.9M | $100.1M | $159.6M |
| Total liabilities | $57.2M | $47.4M | $49.3M | $60.5M | $94.3M |
Shares outstanding 32.3M
Annual filing data through FY ended December 31, 2025; float as of July 2, 2026.